Related references
Note: Only part of the references are listed.2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Gerhard Hindricks et al.
EUROPEAN HEART JOURNAL (2021)
Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients
Danilo Menichelli et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
Comparative effectiveness of oral anticoagulants in everyday practice
A. John Camm et al.
HEART (2021)
Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation
M. Jansson et al.
THROMBOSIS RESEARCH (2020)
Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation A Systematic Review and Meta-Analysis
Aya F. Ozaki et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2020)
Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies
Shahrzad Salmasi et al.
BMJ OPEN (2020)
Non-vitamin K antagonist oral anticoagulation agents in patients with atrial fibrillation: Insights from Italian monitoring registries
P. P. Olimpieri et al.
IJC HEART & VASCULATURE (2020)
Latent Classes of Adherence to Oral Anticoagulation Therapy Among Patients With a New Diagnosis of Atrial Fibrillation
Nemin Chen et al.
JAMA NETWORK OPEN (2020)
Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK
Ana Ruigomez et al.
BMJ OPEN (2019)
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
Brandon K. Martinez et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Pharmacokinetics of new oral anticoagulants: implications for use in routine care
Ylenia Ingrasciotta et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation
Maja Hellfritzsch et al.
EUROPACE (2017)
The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation
Laura Fanning et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction
Xiaoxi Yao et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Peter Bronnum Nielsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Peter Bronnum Nielsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic
Faris Al-Khalili et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation
Jan Beyer-Westendorf et al.
EUROPACE (2016)
Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?
S. Desmaele et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care
Anders Gorst-Rasmussen et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2016)
Thromboprophylaxis in patients with atrial fibrillation: a real practice analysis
Paola Deambrosis et al.
GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT (2016)
Epidemiology of atrial fibrillation: European perspective
Massimo Zoni-Berisso et al.
CLINICAL EPIDEMIOLOGY (2014)
Application of randomized clinical trial data to actual practice: apixaban therapy for reduction of stroke risk in non-valvular atrial fibrillation patients
Alpesh Amin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database
Sally Lee et al.
BMJ OPEN (2012)
The use of propensity scores to assess the generalizability of results from randomized trials
Elizabeth A. Stuart et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Treating Individuals 1 - External validity of randomised controlled trials: To whom do the results of this trial apply?'
PM Rothwell
LANCET (2005)
Share Paper
